Hemovent GMBH
Portable heart-lung machine for bedside use
This article was originally published in Start Up
Executive Summary
Hemovent GMBH has developed a miniaturized extracorporeal membrane oxygenation system for bedside use in intensive care. The start-up says the footprint of its ECMO is just 10% the size of the smallest commercially available heart-lung machine, and the cost of the unit is 95% less than a standard ECMO device.
You may also be interested in...
Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: